Retina Avascular Persistente Medida por Angiografía con Fluoresceína Oral en Pacientes con Retinopatía del Prematuro Tratados con Antiangiogénico
Luis Gilberto Pérez-Chimal, Gabriel Alejandro Gómez -Martínez, Carlos Rafael Vargas-Riaño, María Ana Martínez-Castellanos
Keywords :
Retina avascular persistente, RAP, Retinopatía del Prematuro, ROP, Angiografía con Fluoresceína, FAG, láser, antiangiogénico, retina, oxígeno
Citation Information :
Pérez-Chimal LG, -Martínez GA, Vargas-Riaño CR, Martínez-Castellanos MA. Retina Avascular Persistente Medida por Angiografía con Fluoresceína Oral en Pacientes con Retinopatía del Prematuro Tratados con Antiangiogénico. 2024; 17 (3):4-12.
La retina avascular persistente (RAP) es una entidad que sucede principalmente en Retinopatía del Prematuro (ROP) tratada con antiangiogénicos o autolimitada, así como en otras vasculopatías retinianas infantiles y que puede generar complicaciones a largo plazo como neovascularización, hemorragia vítrea, regmas retinianos y desprendimiento de retina.
La angiografía con fluoresceína es el estándar diagnóstico ya que identifica los cambios vasculares en la unión de la retina avascular y vascular, realizamos un estudio transversal en 24 pacientes tratados con Anti-VEGF para ROP tipo 1 a las 65 semanas de edad corregida, con una edad gestacional media de 29.3 semanas de gestación (26-34 Semanas), y un peso al nacimiento de 1,025g (550g -2,000g). Los pacientes fueron tratados a las 37.3 semanas corregidas.
En nuestro estudio mediante fluoresceína vía oral calculado a 25 mg/kg, disuelto en 1 onza de leche (30 ml) con 3 horas de ayuno para favorecer su absorción, identificamos retina avascular en 75% de los pacientes, cambios vasculares en 58.3%, tortuosidad vascular en 41.6% y neovascularización en 16.6%. Los pacientes con neovascularización y retina avascular persistente fueron tratados con fotocoagulación láser con técnica de disparos confluentes.
Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, Binenbaum G, Blair M, Peter Campbell J, Capone A Jr, Chen Y, Dai S, Ells A, Fleck BW, Good WV, Elizabeth Hartnett M, Holmstrom G, Kusaka S, Kychenthal A, Lepore D, Lorenz B, Martinez-Castellanos MA, Özdek Ş, Ademola-Popoola D, Reynolds JD, Shah PK, Shapiro M, Stahl A, Toth C, Vinekar A, Visser L, Wallace DK, Wu WC, Zhao P, Zin A. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016/j.ophtha.2021.05.031. Epub 2021 Jul 8. PMID: 34247850; PMCID: PMC10979521.
Warren CC, Young JB, Goldberg MR, Connor TB, Kassem IS, Costakos DM. Findings in Persistent Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2018 Jul 1;49(7):497-503. doi: 10.3928/23258160-20180628-05. PMID: 30021036; PMCID: PMC6196355.
Al-Taie R, Simkin SK, Douçet E, Dai S. Persistent Avascular Retina in Infants With a History of Type 2 Retinopathy of Prematurity: To Treat or Not to Treat? J Pediatr Ophthalmol Strabismus. 2019 Jul 1;56(4):222-228. doi: 10.3928/01913913-20190501-01. PMID: 31322711.
McCannel C, Atebara N, Kim S, et al. Chapter 8: Retinopathy of Prematu- rity. Basic Clinical and Science Course Section 12: Retina and Vitreous. San Francisco, CA: AAO. 2018–2019; 175–187.
Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022 Oct 14;36(3):239-242. doi: 10.4103/sjopt.sjopt_18_22. PMID: 36276256; PMCID: PMC9583358.
Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. The Early Treatment for Retinopathy Of Prematurity Study: structural findings at age 2 years. Br J Ophthalmol. 2006 Nov;90(11):1378-82. doi: 10.1136/bjo.2006.098582. Epub 2006 Aug 16. PMID: 16914473; PMCID: PMC1857487.
Hanif AM, Gensure RH, Scruggs BA, Anderson J, Chiang MF, Campbell JP. Prevalence of persistent avascular retina in untreated children with a history of retinopathy of prematurity screening. J AAPOS. 2022 Feb;26(1):29-31. doi: 10.1016/j.jaapos.2021.09.004. Epub 2021 Dec 4. PMID: 34875370; PMCID: PMC9019990.
Mansukhani SA, Hutchinson AK, Neustein R, Schertzer J, Allen JC, Hubbard GB. Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression. Ophthalmol Retina. 2019 May;3(5):436-443. doi: 10.1016/j.oret.2019.01.016. Epub 2019 Jan 31. PMID: 31044736; PMCID: PMC6501804.
Harper CA 3rd, Wright LM, Young RC, Read SP, Chang EY. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY. Retina. 2019 Apr;39(4):700-705. doi: 10.1097/IAE.0000000000001996. PMID: 29300248.
Al Rasheed R, Adhi MI, Alowedi SA, Albdah B, Aldebasi T, Hazzazi MA. Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography. Int J Retina Vitreous. 2022 Aug 2;8(1):53. doi: 10.1186/s40942-022-00402-3. PMID: 35918740; PMCID: PMC9344754.
Martinez-Castellanos MA, Velez-Montoya R, Price K, Henaine-Berra A, García-Aguirre G, Morales-Canton V, Cernichiaro-Espinosa LA. Vascular changes on fluorescein angiography of premature infants with low risk of retinopathy of prematurity after high oxygen exposure. Int J Retina Vitreous. 2017 Jan 16;3:2. doi: 10.1186/s40942-016-0055-6. PMID: 28105373; PMCID: PMC523851.
Uner OE, Rao P, Hubbard GB 3rd. Reactivation of Retinopathy of Prematurity in Adults and Adolescents. Ophthalmol Retina. 2020 Jul;4(7):720-727. doi: 10.1016/j.oret.2020.02.001. Epub 2020 Feb 11. PMID: 32224099; PMCID: PMC7354214.
Özdemir HB, Özdek S. Late sequelae of retinopathy of prematurity in adolescence and adulthood. Saudi J Ophthalmol. 2022 Oct 14;36(3):270-277. doi: 10.4103/sjopt.sjopt_276_21. PMID: 36276258; PMCID: PMC9583352.
Hamad AE, Moinuddin O, Blair MP, Schechet SA, Shapiro MJ, Quiram PA, Mammo DA, Berrocal AM, Prakhunhungsit S, Cernichiaro-Espinosa LA, Mukai S, Yonekawa Y, Ung C, Holz ER, Harper CA 3rd, Young RC, Besirli CG, Nagiel A, Lee TC, Gupta MP, Walsh MK, Khawly JA, Campbell JP, Kychenthal A, Nudleman ED, Robinson JE, Hartnett ME, Calvo CM, Chang EY. Late-Onset Retinal Findings and Complications in Untreated Retinopathy of Prematurity. Ophthalmol Retina. 2020 Jun;4(6):602-612. doi: 10.1016/j.oret.2019.12.015. Epub 2019 Dec 24. PMID: 32059986; PMCID: PMC7282927.
Vural A, Ekinci DY, Onur IU, Hergünsel GO, Yiğit FU. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression. Int Ophthalmol. 2019 Oct;39(10):2267-2274. doi: 10.1007/s10792-018-01064-7. Epub 2019 Jan 2. PMID: 30604251.
Beck KD, Rahman EZ, Ells A, Mireskandari K, Berrocal AM, Harper CA. SAFER-ROP: updated protocol for anti-VEGF injections for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2020;51(7):402–406. doi: 10.3928/23258160-20200702-05
da Cruz NFS, Hoyek S, Sengillo JD, Rodríguez A, de Oliveira G, Negron CI, Patel NA, Berrocal AM. Fluorescein Angiography Parameters in Premature Neonates. Ophthalmol Sci. 2024 May 29;4(6):100561. doi: 10.1016/j.xops.2024.100561. PMID: 39132023; PMCID: PMC11315194.
Ali SMA, Khan I, Khurram D, Kozak I. Ultra-Widefield Angiography With Oral Fluorescein in Pediatric Patients With Retinal Disease. JAMA Ophthalmol. 2018 May 1;136(5):593-594. doi: 10.1001/jamaophthalmol.2018.0462. PMID: 29621363; PMCID: PMC6583855.
Chee RI, Gupta MP, Valikodath NG, Cole E, Orlin A, Al-Khaled T, Rusu I, Patel SN, Han J, Yap V, Jonas KE, Campbell PJ, Chiang MF, Chan RVP. Evaluation of Potential Systemic Adverse Events Related to Fluorescein Angiography in Pediatric Patients. Ophthalmol Retina. 2020 Jun;4(6):595-601. doi: 10.1016/j.oret.2019.12.012. Epub 2019 Dec 16. PMID: 32146220; PMCID: PMC7880605.
